Exhibit 99.1 LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights VIZZ (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia TM Commercial product launch initiated in October 2025 with broad product availability in mid-Q4 2025 Additional Third Quarter 2025 and Recent Corporate Highlights Over 2,500 ECPs prescribed VIZZ, 40% of which have prescribed multiple times, resulting in over 5,000 prescriptions filled through October 202 ...